Acadia Pharmaceuticals announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals head of R&D, Doug Williamson, M.D., to leave
- Acadia Pharmaceuticals price target raised to $40 from $38 at Canaccord
- Mizuho upgrades Acadia to Buy on strengthening fundamentals
- Acadia Pharmaceuticals upgraded to Buy from Neutral at Mizuho
- Acadia Pharmaceuticals price target raised to $42 from $39 at JMP Securities